EXPRESSION VECTOR FOR CREATING IMMUNOBIOLOGICAL AGENT FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) Russian patent published in 2020 - IPC C12N15/86 A61K39/215 

FIELD: biotechnology.

SUBSTANCE: invention refers to biotechnology, immunology and virology. It concerns recombinant vectors which can be used in pharmaceutical industry for creation of immunobiological agent for induction of specific immunity against virus of severe acute respiratory syndrome SARS-CoV-2. Expression vector comprising a genome of a recombinant human adenovirus strain of 26^th serotype in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (embodiment 1). Maternal sequence of human adenovirus of 26^th serotype is SEQ ID NO: 5. Furthermore, an expression vector comprising a genome of the recombinant strain of simian adenovirus of 25^th serotype in which the E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 (embodiment 2). Maternal sequence of simian adenovirus of 25^th serotype is SEQ ID NO: 6. Besides, an expression vector of a genome-containing recombinant human adenovirus strain of 5^th serotype in which E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (embodiment 3). Maternal sequence of human adenovirus of 5^th serotype is SEQ ID NO: 7. Method of using the developed expression vector for creating an immunobiological agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2 is also disclosed.

EFFECT: invention enables to obtain a stable immune response to SARS-Cov-2 glycoprotein.

7 cl, 2 tbl, 5 ex